(Image source: Photo.com)
Recently, Shenzhen Cis Juhe Biotechnology Co., Ltd. (hereinafter referred to as "Juhe Biotechnology") announced the completion of more than 100 million yuan in Series B financing. The round was led by Prosperity7 Ventures, a diversified growth fund owned by Aramco Ventures, with additional investment from long-standing shareholder Shanlan Capital. This new funding will strongly promote the company's global business expansion, product development, registration and declaration, public health management and consumer medical sector development, and bring efficient solutions to many users.
Juhe Biotech takes women's health as the core of scientific and technological innovation, and is committed to filling the gap in the field of women's health. The company has successfully launched methylation detection products and female reproductive microecological detection products for early screening of gynecological tumors. Among them, Juhe Bio's core product Hegongkang CISCER® (National Machinery Approval 20233400253) was approved for marketing by the State Food and Drug Administration of China in March this year. The dual-target gene selected for this product has been included in the "Blue Book of Tertiary Standardized Prevention and Treatment of Cervical Cancer in China", and it is recommended that it be used in multiple application scenarios in the diagnosis and treatment of cervical cancer.
In addition to the products that have been marketed, Juhe Biotech is also improving the layout of early screening and early diagnosis of gynecological tumors, and the endometrial cancer screening product (CISENDO), which has invested nearly 100 million yuan, has completed clinical trials, and the ovarian cancer methylation product (CISOVA) is in clinical trials.
DNA methylation has a variety of characteristics that make it an effective biomarker for the early diagnosis of cervical cancer, and the results of rapid progression of cervical cancer or epithelial lesions can be known by detection by clinically proven technologies such as fluorescence quantitative polymerase chain reaction, next-generation sequencing, or microarray.
In terms of clinical translational research, Juhe Biotech has carried out 3 national-level multi-center studies of 10,000 people, multiple provincial-level studies and a Sino-European transnational study. At present, the company cooperates with top institutions in Southeast Asia, Europe and other places to actively carry out academic and marketing activities.
-- The growing female population Health problems cannot be ignored
The large and growing female population provides a huge space for the women's health services market. Due to physiological structure, women have a higher prevalence of some diseases than men, becoming one of the most common groups. Ali Health, together with the five major physical examination institutions of iKang Guobin, Ciming Physical Examination, Ruici Physical Examination, Arrail Dental and Meinian Health, released the "Chinese Women's Physical Examination Health Data Report", which analyzes the health status and high-incidence causes of women of different ages through physical examination data in recent years. The details are as follows:
-- The potential market space for early cancer screening is huge
In the future, with the gradual maturity of cancer screening technology and products, people's acceptance of early cancer screening will gradually increase, and the potential market space for early cancer screening is huge. According to Burning Rock Therapeutics' prospectus for China's early cancer screening market, the market size of early cancer screening in mainland China will grow from US$18.4 billion in 2019 to US$28.9 billion in 2030, with a compound annual growth rate of about 4.2%.
Aysar Tayeb, Managing Director of Prosperity7 Ventures, the lead investor in this round of financing, said, "We are very pleased to lead the Series B financing of Juhe Biotech. Prosperity7 Ventures is committed to supporting impactful companies, and Juhe Biotech is one such company that has made outstanding achievements in early detection of diseases. As Juhe Biotech accelerates its global market expansion and focuses on improving women's health more broadly, we are confident that the company will be more successful." ”
With the improvement of people's health awareness and the continuous progress of medical technology, the market demand for early cancer screening continues to grow. At the same time, the government's attention and support for health management also provides a good policy environment for the development of the early screening industry. With the application of new technologies such as big data and artificial intelligence, early cancer screening technology will continue to innovate and bring more development opportunities to the industry.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "Analysis Report on China's Pharmaceutical Commercial Market Prospect and Investment Strategic Planning" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certification, IPO consulting/fundraising feasibility study, IPO working paper consulting, etc. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers.